Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pulmonx (LUNG) EBITDA Margin (2019 - 2025)

Pulmonx (LUNG) has disclosed EBITDA Margin for 7 consecutive years, with 66.76% as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA Margin fell 14.0% to 66.76% in Q3 2025 year-over-year; TTM through Sep 2025 was 62.24%, a 903.0% increase, with the full-year FY2024 number at 67.93%, up 1911.0% from a year prior.
  • EBITDA Margin was 66.76% for Q3 2025 at Pulmonx, down from 61.78% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 57.21% in Q4 2024 to a low of 149.25% in Q1 2022.
  • A 5-year average of 88.67% and a median of 84.4% in 2023 define the central range for EBITDA Margin.
  • Biggest YoY gain for EBITDA Margin was 21958bps in 2021; the steepest drop was -5843bps in 2021.
  • Pulmonx's EBITDA Margin stood at 93.65% in 2021, then grew by 2bps to 91.44% in 2022, then increased by 25bps to 68.43% in 2023, then rose by 16bps to 57.21% in 2024, then dropped by -17bps to 66.76% in 2025.
  • Per Business Quant, the three most recent readings for LUNG's EBITDA Margin are 66.76% (Q3 2025), 61.78% (Q2 2025), and 63.71% (Q1 2025).